Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry

被引：0
|
作者：
Michael Guger
Christian Enzinger
Fritz Leutmezer
Franziska Di Pauli
Jörg Kraus
Stefan Kalcher
Erich Kvas
Thomas Berger
机构：
[1] Kepler University Hospital GmbH,Clinic for Neurology 2, Med Campus III
[2] Johannes Kepler University Linz,Medical Faculty
[3] Medical University of Graz,Department of Neurology
[4] Medical University of Vienna,Department of Neurology
[5] Medical University of Innsbruck,Clinical Department of Neurology
[6] Paracelsus Medical University and Salzburger Landeskliniken,Department of Laboratory Medicine
[7] Heinrich-Heine-University,Department of Neurology, Medical Faculty
[8] Hermesoft,undefined
[9] Data management,undefined
[10] Hermesoft,undefined
[11] Statistics,undefined
来源：
Journal of Neurology | 2021年 / 268卷
关键词：
Disability progression; Long-term; Multiple sclerosis; Natalizumab; Predictor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4303 / 4310
页数：7
相关论文
共 50 条
  • [31] JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients
    Pabitra Basnyat
    Elina Virtanen
    Irina Elovaara
    Sanna Hagman
    Eeva Auvinen
    Journal of NeuroVirology, 2017, 23 : 734 - 741
  • [32] JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients
    Basnyat, Pabitra
    Virtanen, Elina
    Elovaara, Irina
    Hagman, Sanna
    Auvinen, Eeva
    JOURNAL OF NEUROVIROLOGY, 2017, 23 (05) : 734 - 741
  • [33] JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients
    Basnyat, P.
    Virtanen, E.
    Elovaara, I.
    Hagman, S.
    Auvinen, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 843 - 843
  • [34] Long-term quality of life outcome in subjects with multiple sclerosis responding to treatment with fampridine
    Rodriguez-Leal, F. A.
    Eisele, J.
    Hainke, U.
    Konofalska, U.
    Thomas, K.
    Schultheiss, T.
    Ziemssen, T.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 387 - 388
  • [35] The importance of long-term data in multiple sclerosis
    Montalban, Xavier
    JOURNAL OF NEUROLOGY, 2006, 253 (Suppl 6) : 9 - 15
  • [36] The importance of long-term data in multiple sclerosis
    Xavier Montalban
    Journal of Neurology, 2006, 253 : vi9 - vi15
  • [37] No evidence of disease activity status among patients with relapsing-remitting multiple sclerosis on long-term natalizumab treatment: data from a real-world cohort in the Czech Republic
    Horakova, D.
    Vaneckova, M.
    Krasensky, J.
    Seidl, Z.
    van Pesch, V.
    van Wijmeersch, B.
    Ribbens, A.
    van Hecke, W.
    Freudensprung, U.
    Hyde, R.
    Ho, P. -R.
    Kokic, M.
    Uher, T.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 409 - 410
  • [38] Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data
    Noteboom, S.
    Strijbis, E. M. M.
    Coerver, E. M. E.
    Colato, E.
    van Kempen, Z. L. E.
    Jasperse, B.
    Vrenken, H.
    Killestein, J.
    Schoonheim, M. M.
    Steenwijk, M. D.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 87
  • [39] Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry
    Frahm, Niklas
    Ellenberger, David
    Stahmann, Alexander
    Fneish, Firas
    Lueftenegger, Daniel
    Salmen, Hans C.
    Schirduan, Ksenija
    Schaak, Tom P. A.
    Flachenecker, Peter
    Kleinschnitz, Christoph
    Paul, Friedemann
    Krefting, Dagmar
    Zettl, Uwe K.
    Peters, Melanie
    Warnke, Clemens
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [40] Long-term outcomes in natalizumab-treated patients who were free of disease activity over the 2-year AFFIRM study
    Rudick, R.
    Kappos, L.
    Polman, C.
    Goodman, A.
    Lublin, F.
    O'Connor, P.
    Moreau, T.
    Forrestal, F.
    Hotermans, C.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S219 - S220
12345